MedPath

The effect of luseogliflozin on epicardial fat accumulation in obese patients with type 2 diabetes

Not Applicable
Conditions
Type 2 diabetes
Registration Number
JPRN-UMIN000019072
Lead Sponsor
kyo Medical and Dental University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
20
Inclusion Criteria

Not provided

Exclusion Criteria

Patients who are taking SGLT2 inhibitors Patients with insulin treatment Patients with active infection, malignancy, severe liver or renal diseases Patients who are unable to figure out the consent due to dementia or impairment of consciousness Pregnant women, lactating woman, women who are planning to get pregnant Patients whose treatment for diabetes were changed 3 months prior to baseline evaluation

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The change of epicardial fat volume at 12 weeks
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath